HINGE BIO, INC.

Profile

Company Names

HINGE BIO, INC.

Addresses

863 MITTEN ROAD, SUITE 100L, BURLINGAME, CA 94010

Phone Numbers

(650) 488-7070

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2015

State Incorporated:

DELAWARE

Total Amount Raised:

$66,788,127.00

Number of Funding Rounds:

3
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
3
2024-12-31 
$30,596,388.00 
$40,800,009.00 
$10,203,621.00 
Equity 
2
2020-12-18 
$18,000,000.00 
$18,000,000.00 
$0.00 
Debt 
1
2020-02-11 
$18,191,739.00 
$19,042,038.00 
$850,299.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
DANIEL 
 
CAPON 
EXECUTIVE OFFICER, DIRECTOR
HINGE BIO, INC.
DANIEL 
J. 
CAPON 
DIRECTOR
HINGE BIO, INC.
MALCOLM 
 
GEFTER 
DIRECTOR
STELLAR BIOTECHNOLOGIES INC.   |  HINGE BIO, INC.
MALCOLM 
L. 
GEFTER 
DIRECTOR
HINGE BIO, INC.
JEFFREY 
 
LONG-MCGIE 
DIRECTOR
CARIBOU BIOSCIENCES, INC.   |  HINGE BIO, INC.
J. 
MISHA 
PETKEVICH 
DIRECTOR
V2M LIFE SCIENCES FUND LP   |  HINGE BIO, INC.
JOHN 
MISHA 
PETKEVICH 
DIRECTOR
HINGE BIO, INC.
CARIN 
 
ROLLINS 
EXECUTIVE OFFICER, DIRECTOR
HINGE BIO, INC.
CARIN 
M. 
ROLLINS 
EXECUTIVE OFFICER, DIRECTOR
HINGE BIO, INC.
SAMUEL 
 
SAKS 
DIRECTOR
AUSPEX PHARMACEUTICALS, INC.   |  TONIX PHARMACEUTICALS HOLDING CORP.   |  BULLET BIOTECHNOLOGY, INC.   |  HINGE BIO, INC.   |  QUANTA THERAPEUTICS, INC.
HAROLD 
E. 
SELICK, PHD 
EXECUTIVE OFFICER, DIRECTOR
HINGE BIO, INC.
MIRIAM 
 
SIEKEVITZ 
EXECUTIVE OFFICER
HINGE BIO, INC.
ALEX 
 
SILVERSTEIN 
DIRECTOR
HINGE BIO, INC.
WILLIAM 
 
UNGER 
DIRECTOR
HINGE BIO, INC.
WILLIAM 
D. 
UNGER 
DIRECTOR
HINGE BIO, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2025-01-15
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2024-12-31 
2021-02-01
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2020-12-18 
2021-01-14
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2020-12-18 
2021-01-07
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2020-12-18 
2020-04-28
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2020-02-11 
2020-02-27
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2020-02-11 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
ARCADIA SECURITIES, LLC
44656
NONE
NONE
ARCADIA SECURITIES, LLC
44656
BROOKLINE CAPITAL MARKETS, A DIVISION OF ARCADIA SECURITIES, LLC
44656
SCOTT A. KATZMANN
1087840